The Potential Drug Target ASB14: Ankyrin Repeat and SOCS Box Containing 14

Target Name: ASB14

NCBI ID: G142686

ASB14

The Potential Drug Target ASB14: Ankyrin Repeat and SOCS Box Containing 14

Abstract:

ASB14, or Ankyrin Repeat and SOCS Box Containing 14, is a highly conserved non-coding RNA molecule that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This article will summarize the current research on ASB14, including its identification as a potential drug target, its potential mechanisms of action, and ongoing clinical trials.

Introduction:

The Ankyrin repeat and SOCS box containing 14 (ASB14) is a non-coding RNA molecule that has been identified in various organisms, including humans. It is characterized by the presence of an Ankyrin repeat and a SOCS box, which are both unique features that have been observed in various RNA molecules. While the functions of ASB14 remain poorly understood, it has been shown to play important roles in various cellular processes, including cell signaling, DNA replication, and transcript regulation.

Identification as a Potential Drug Target:

The potential drug target status of ASB14 is supported by several studies. First, several studies have shown that ASB14 can interact with various protein molecules and drugs, including inhibitors of the protein kinase CKL (Kyr30) and the DNA replication protein, DNRT1. Second, Several studies have shown that ASB14 can be targeted by small molecules, including inhibitors of the RNA polymerase II (RNA-II) subunit, which is responsible for transcribing DNA into RNA.

Potential Mechanisms of Action:

The potential mechanisms of action of ASB14 as a drug target are still being explored. However, several studies have suggested that ASB14 may play a role in cell signaling by regulating the activity of various signaling pathways, including the TGF-β pathway, the PI3K/ Akt pathway, and the NF-kappa-B pathway.

One potential mechanism of action for ASB14 may be through its role in regulating the activity of the protein kinase CKL (Kyr30), which is known to play a role in promoting the growth and survival of various cancer cells. Several studies have shown that ASB14 can interact with Kyr30 and can inhibit its activity, leading to the conclusion that ASB14 may be a potential drug target for cancer.

Another potential mechanism of action for ASB14 may be through its role in regulating the activity of the DNA replication protein, DNRT1. DNRT1 is known to play a critical role in the regulation of DNA replication, and several studies have shown that ASB14 can interact with DNRT1 and can inhibit its activity, leading to the conclusion that ASB14 may be a potential drug target for neurodegenerative diseases.

Ongoing Clinical Trials:

At present, research on ASB14 mainly focuses on two aspects: drug screening and drug target verification.

In terms of drug screening, some studies have explored the possibility of ASB14 as a drug target. For example, studies have found that ASB14 can bind to the small molecule compound EtBr and be specifically enriched in cells. In addition, ASB14 was also found to significantly inhibit the activity of CKL, indicating that ASB14 may be a potential drug target.

In terms of drug target validation, although no drugs targeting ASB14 have yet been approved, some studies have explored other possibilities of ASB14 as a drug target. For example, studies have shown that ASB14 may bind to glutathione (GSH) and affect GSH levels. In addition, ASB14 was also found to significantly inhibit the activity of nuclear factor kappa B (NF-kappa-B) in cells, indicating that ASB14 may be a drug target related to NF-kappa-B.

Conclusion:

ASB14 is a highly conserved non-coding RNA molecule that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential drug target status of AS

Protein Name: Ankyrin Repeat And SOCS Box Containing 14

Functions: May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "ASB14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASB14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets